These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 9777325)

  • 21. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
    García Díaz E; Martín Folgueras T
    Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity and type 2 diabetes: a conflict of interests?
    Williams G
    Int J Obes Relat Metab Disord; 1999 Jun; 23 Suppl 7():S2-4. PubMed ID: 10455464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Managing type 2 diabetes mellitus in patients with obesity.
    Hauner H
    Treat Endocrinol; 2004; 3(4):223-32. PubMed ID: 16026105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions.
    Coutinho W
    Arq Bras Endocrinol Metabol; 2009 Mar; 53(2):262-70. PubMed ID: 19466219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.
    Sari R; Balci MK; Cakir M; Altunbas H; Karayalcin U
    Endocr Res; 2004 May; 30(2):159-67. PubMed ID: 15473126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiobesity pharmacotherapy in the management of type 2 diabetes.
    Scheen AJ; Lefèbvre PJ
    Diabetes Metab Res Rev; 2000; 16(2):114-24. PubMed ID: 10751751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The new role of pharmacotherapy for weight reduction in obesity.
    Fernstrom MH; Fernstrom JD
    Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Weight reduction. Antiobesity drug treatment in type-2 diabetics].
    Verspohl EJ
    Pharm Unserer Zeit; 2002; 31(3):300-7. PubMed ID: 12071127
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of weight-reducing agents on glycaemic parameters and progression to Type 2 diabetes: a review.
    Lloret-Linares C; Greenfield JR; Czernichow S
    Diabet Med; 2008 Oct; 25(10):1142-50. PubMed ID: 19046191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
    Sabuncu T; Nazligul Y; Karaoglanoglu M; Ucar E; Kilic FB
    Rom J Gastroenterol; 2003 Sep; 12(3):189-92. PubMed ID: 14502318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
    Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS
    Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.
    Valsamakis G; McTernan PG; Chetty R; Al Daghri N; Field A; Hanif W; Barnett AH; Kumar S
    Metabolism; 2004 Apr; 53(4):430-4. PubMed ID: 15045687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.
    Gursoy A; Erdogan MF; Cin MO; Cesur M; Baskal N
    Eat Weight Disord; 2006 Dec; 11(4):e127-32. PubMed ID: 17272944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Wang TF; Pei D; Li JC; Tsai WC; Tsai CC; Yao CY; Chang ET; Hsieh MC; Su KY; Kuo SW
    Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy for obesity.
    Halford JC
    Appetite; 2006 Jan; 46(1):6-10. PubMed ID: 16229924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
    Van Gaal LF; Wauters MA; De Leeuw IH
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Orlistat: a review of its use in the management of obesity.
    Henness S; Perry CM
    Drugs; 2006; 66(12):1625-56. PubMed ID: 16956313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.